Index - 2020
2021 / 2020 / 2019 / 2018
Explanation of abbreviations
- Other
- Main articleH
- Attention!LO
- New
ACE inhibitors
NSAID
2020
angiotensin II receptor antagonists
2020
coronavirus
2020
corticosteroids
2020
covid-19
2020
pioglitazone
2020
sars-cov-2
2020
Achilles tendon rupture
ACP
202052-55
PRP
202052-55
autologous conditioned plasma
202052-55
autologous platelet-rich plasma
202052-55
platelet-rich plasma
202052-55
rotator cuff rupture
202052-55
soft tissue injuries
202052-55
tendinopathy
202052-55
ACP
Achilles tendon rupture
202052-55
PRP
202052-55
autologous conditioned plasma
202052-55
autologous platelet-rich plasma
202052-55
platelet-rich plasma
202052-55
rotator cuff rupture
202052-55
soft tissue injuries
202052-55
tendinopathy
202052-55
acute chest syndrome
hydroxycarbamide
202057-64
pain episodes
202057-64
sickle cell disease
202057-64
anakinra
C1-esterase inhibitor
202067-78
azithromycin
202067-78
chloroquine
202067-78
covid-19
202067-78
hydroxychloroquine
202067-78
icatibant
202067-78
lanadelumab
202067-78
lopinavir
202067-78
remdesivir
202067-78
ritonavir
202067-78
sars-cov-2
202067-78
tocilizumab
202067-78
valsartan
202067-78
zinc
202067-78
angiotensin II receptor antagonists
ACE inhibitors
2020
NSAID
2020
coronavirus
2020
corticosteroids
2020
covid-19
2020
pioglitazone
2020
sars-cov-2
2020
antibiotic-resistant bacteria
H2 antagonists
202085-88
PPIs
202085-88
gastric acid-suppressive agent
202085-88
intestinal colonisation
202085-88
reboundeffect
202085-88
antithrombotic
CYP2C19
20209-14
Cytochrome P450
20209-14
PCI
20209-14
clopidogrel
20209-14
genotyping
20209-14
autologous conditioned plasma
ACP
202052-55
Achilles tendon rupture
202052-55
PRP
202052-55
autologous platelet-rich plasma
202052-55
platelet-rich plasma
202052-55
rotator cuff rupture
202052-55
soft tissue injuries
202052-55
tendinopathy
202052-55
autologous platelet-rich plasma
ACP
202052-55
Achilles tendon rupture
202052-55
PRP
202052-55
autologous conditioned plasma
202052-55
platelet-rich plasma
202052-55
rotator cuff rupture
202052-55
soft tissue injuries
202052-55
tendinopathy
202052-55
azithromycin
C1-esterase inhibitor
202067-78
anakinra
202067-78
chloroquine
202067-78
covid-19
202067-78
hydroxychloroquine
202067-78
icatibant
202067-78
lanadelumab
202067-78
lopinavir
202067-78
remdesivir
202067-78
ritonavir
202067-78
sars-cov-2
202067-78
tocilizumab
202067-78
valsartan
202067-78
zinc
202067-78
Ballerine
Pearl Index
2020123-127
contraception
2020123-127
copper IUD
2020123-127
copper-containing IUD
2020123-127
medical device
2020123-127
notified body
2020123-127
pregnancy
2020123-127
bias
RCT
20201-8
consistency check
202089-95
drugs ranking
202089-95
effect modifier
202089-95
network meta-analysis
202089-95
observational
20201-8
randomised
20201-8
research
20201-8
statistical test
202089-95
breast cancer
hormone therapy
202022-27
menopausal symptoms
202022-27
breast implant
lymphoma
2020
C1-esterase inhibitor
anakinra
202067-78
azithromycin
202067-78
chloroquine
202067-78
covid-19
202067-78
hydroxychloroquine
202067-78
icatibant
202067-78
lanadelumab
202067-78
lopinavir
202067-78
remdesivir
202067-78
ritonavir
202067-78
sars-cov-2
202067-78
tocilizumab
202067-78
valsartan
202067-78
zinc
202067-78
cardiovascular mortality
Entresto
2020
enalapril
2020
heart failure
2020
sacubitril
2020
valsartan
2020
chloroquine
C1-esterase inhibitor
202067-78
anakinra
202067-78
azithromycin
202067-78
covid-19
202067-78
hydroxychloroquine
202067-78
icatibant
202067-78
lanadelumab
202067-78
lopinavir
202067-78
remdesivir
202067-78
ritonavir
202067-78
sars-cov-2
202067-78
tocilizumab
202067-78
valsartan
202067-78
zinc
202067-78
clopidogrel
CYP2C19
20209-14
Cytochrome P450
20209-14
PCI
20209-14
antithrombotic
20209-14
genotyping
20209-14
consistency check
bias
202089-95
drugs ranking
202089-95
effect modifier
202089-95
network meta-analysis
202089-95
statistical test
202089-95
contaminations
drug contamination
2020121-122
impurities
2020121-122
preparations
2020121-122
production process
2020121-122
quality control
2020121-122
valsartan
2020121-122
contraception
Ballerine
2020123-127
Pearl Index
2020123-127
copper IUD
2020123-127
copper-containing IUD
2020123-127
medical device
2020123-127
notified body
2020123-127
pregnancy
2020123-127
copper IUD
Ballerine
2020123-127
Pearl Index
2020123-127
contraception
2020123-127
copper-containing IUD
2020123-127
medical device
2020123-127
notified body
2020123-127
pregnancy
2020123-127
copper-containing IUD
Ballerine
2020123-127
Pearl Index
2020123-127
contraception
2020123-127
copper IUD
2020123-127
medical device
2020123-127
notified body
2020123-127
pregnancy
2020123-127
coronavirus
ACE inhibitors
2020
NSAID
2020
angiotensin II receptor antagonists
2020
corticosteroids
2020
covid-19
2020
pioglitazone
2020
sars-cov-2
2020
corticosteroids
ACE inhibitors
2020
NSAID
2020
angiotensin II receptor antagonists
2020
coronavirus
2020
covid-19
2020
pioglitazone
2020
sars-cov-2
2020
covid-19
ACE inhibitors
2020
C1-esterase inhibitor
202067-78
NSAID
2020
anakinra
202067-78
angiotensin II receptor antagonists
2020
azithromycin
202067-78
chloroquine
202067-78
coronavirus
2020
corticosteroids
2020
hydroxychloroquine
202067-78
icatibant
202067-78
lanadelumab
202067-78
lopinavir
202067-78
pioglitazone
2020
remdesivir
202067-78
ritonavir
202067-78
sars-cov-2
2020
sars-cov-2
202067-78
tocilizumab
202067-78
valsartan
202067-78
zinc
202067-78
CYP enzymes
drug interaction
202015-20
CYP2C19
Cytochrome P450
20209-14
PCI
20209-14
antithrombotic
20209-14
clopidogrel
20209-14
genotyping
20209-14
Cytochrome P450
CYP2C19
20209-14
PCI
20209-14
antithrombotic
20209-14
clopidogrel
20209-14
genotyping
20209-14
drug contamination
contaminations
2020121-122
impurities
2020121-122
preparations
2020121-122
production process
2020121-122
quality control
2020121-122
valsartan
2020121-122
drug interaction
CYP enzymes
202015-20
drugs ranking
bias
202089-95
consistency check
202089-95
effect modifier
202089-95
network meta-analysis
202089-95
statistical test
202089-95
effect modifier
bias
202089-95
consistency check
202089-95
drugs ranking
202089-95
network meta-analysis
202089-95
statistical test
202089-95
enalapril
Entresto
2020
cardiovascular mortality
2020
heart failure
2020
sacubitril
2020
valsartan
2020
Entresto
cardiovascular mortality
2020
enalapril
2020
heart failure
2020
sacubitril
2020
valsartan
2020
gastric acid-suppressive agent
H2 antagonists
202085-88
PPIs
202085-88
antibiotic-resistant bacteria
202085-88
intestinal colonisation
202085-88
reboundeffect
202085-88
genotyping
CYP2C19
20209-14
Cytochrome P450
20209-14
PCI
20209-14
antithrombotic
20209-14
clopidogrel
20209-14
H2 antagonists
PPIs
202085-88
antibiotic-resistant bacteria
202085-88
gastric acid-suppressive agent
202085-88
intestinal colonisation
202085-88
reboundeffect
202085-88
heart failure
Entresto
2020
cardiovascular mortality
2020
enalapril
2020
sacubitril
2020
valsartan
2020
herpes zoster
Shingrix
202097-101
postherpetic neuralgia
202097-101
vaccination programme
202097-101
vaccine
202097-101
hormone therapy
breast cancer
202022-27
menopausal symptoms
202022-27
hydroxycarbamide
acute chest syndrome
202057-64
pain episodes
202057-64
sickle cell disease
202057-64
hydroxychloroquine
C1-esterase inhibitor
202067-78
anakinra
202067-78
azithromycin
202067-78
chloroquine
202067-78
covid-19
202067-78
icatibant
202067-78
lanadelumab
202067-78
lopinavir
202067-78
remdesivir
202067-78
ritonavir
202067-78
sars-cov-2
202067-78
tocilizumab
202067-78
valsartan
202067-78
zinc
202067-78
icatibant
C1-esterase inhibitor
202067-78
anakinra
202067-78
azithromycin
202067-78
chloroquine
202067-78
covid-19
202067-78
hydroxychloroquine
202067-78
lanadelumab
202067-78
lopinavir
202067-78
remdesivir
202067-78
ritonavir
202067-78
sars-cov-2
202067-78
tocilizumab
202067-78
valsartan
202067-78
zinc
202067-78
impurities
contaminations
2020121-122
drug contamination
2020121-122
preparations
2020121-122
production process
2020121-122
quality control
2020121-122
valsartan
2020121-122
interventions
overviews
2020117-120
umbrella review
2020117-120
intestinal colonisation
H2 antagonists
202085-88
PPIs
202085-88
antibiotic-resistant bacteria
202085-88
gastric acid-suppressive agent
202085-88
reboundeffect
202085-88
lanadelumab
C1-esterase inhibitor
202067-78
anakinra
202067-78
azithromycin
202067-78
chloroquine
202067-78
covid-19
202067-78
hydroxychloroquine
202067-78
icatibant
202067-78
lopinavir
202067-78
remdesivir
202067-78
ritonavir
202067-78
sars-cov-2
202067-78
tocilizumab
202067-78
valsartan
202067-78
zinc
202067-78
lopinavir
C1-esterase inhibitor
202067-78
anakinra
202067-78
azithromycin
202067-78
chloroquine
202067-78
covid-19
202067-78
hydroxychloroquine
202067-78
icatibant
202067-78
lanadelumab
202067-78
remdesivir
202067-78
ritonavir
202067-78
sars-cov-2
202067-78
tocilizumab
202067-78
valsartan
202067-78
zinc
202067-78
lymphoma
breast implant
2020
medical device
Ballerine
2020123-127
Pearl Index
2020123-127
contraception
2020123-127
copper IUD
2020123-127
copper-containing IUD
2020123-127
notified body
2020123-127
pregnancy
2020123-127
melatonine
sleep disorders
202041-44
menopausal symptoms
breast cancer
202022-27
hormone therapy
202022-27
mortality rate
vitamin B12
202065-66
vitamin B12 deficiency
202065-66
vitamin B12 supplementation
202065-66
network meta-analysis
bias
202089-95
consistency check
202089-95
drugs ranking
202089-95
effect modifier
202089-95
statistical test
202089-95
notified body
Ballerine
2020123-127
Pearl Index
2020123-127
contraception
2020123-127
copper IUD
2020123-127
copper-containing IUD
2020123-127
medical device
2020123-127
pregnancy
2020123-127
NSAID
ACE inhibitors
2020
angiotensin II receptor antagonists
2020
coronavirus
2020
corticosteroids
2020
covid-19
2020
pioglitazone
2020
sars-cov-2
2020
observational
RCT
20201-8
bias
20201-8
randomised
20201-8
research
20201-8
omega-3 fatty acids
premature birth
202079-84
type 2 diabetes
202079-84
overviews
interventions
2020117-120
umbrella review
2020117-120
pain episodes
acute chest syndrome
202057-64
hydroxycarbamide
202057-64
sickle cell disease
202057-64
PCI
CYP2C19
20209-14
Cytochrome P450
20209-14
antithrombotic
20209-14
clopidogrel
20209-14
genotyping
20209-14
Pearl Index
Ballerine
2020123-127
contraception
2020123-127
copper IUD
2020123-127
copper-containing IUD
2020123-127
medical device
2020123-127
notified body
2020123-127
pregnancy
2020123-127
pioglitazone
ACE inhibitors
2020
NSAID
2020
angiotensin II receptor antagonists
2020
coronavirus
2020
corticosteroids
2020
covid-19
2020
sars-cov-2
2020
platelet-rich plasma
ACP
202052-55
Achilles tendon rupture
202052-55
PRP
202052-55
autologous conditioned plasma
202052-55
autologous platelet-rich plasma
202052-55
rotator cuff rupture
202052-55
soft tissue injuries
202052-55
tendinopathy
202052-55
postherpetic neuralgia
Shingrix
202097-101
herpes zoster
202097-101
vaccination programme
202097-101
vaccine
202097-101
PPIs
H2 antagonists
202085-88
antibiotic-resistant bacteria
202085-88
gastric acid-suppressive agent
202085-88
intestinal colonisation
202085-88
reboundeffect
202085-88
pregnancy
Ballerine
2020123-127
Pearl Index
2020123-127
contraception
2020123-127
copper IUD
2020123-127
copper-containing IUD
2020123-127
medical device
2020123-127
notified body
2020123-127
premature birth
omega-3 fatty acids
202079-84
type 2 diabetes
202079-84
preparations
contaminations
2020121-122
drug contamination
2020121-122
impurities
2020121-122
production process
2020121-122
quality control
2020121-122
valsartan
2020121-122
production process
contaminations
2020121-122
drug contamination
2020121-122
impurities
2020121-122
preparations
2020121-122
quality control
2020121-122
valsartan
2020121-122
PRP
ACP
202052-55
Achilles tendon rupture
202052-55
autologous conditioned plasma
202052-55
autologous platelet-rich plasma
202052-55
platelet-rich plasma
202052-55
rotator cuff rupture
202052-55
soft tissue injuries
202052-55
tendinopathy
202052-55
quality control
contaminations
2020121-122
drug contamination
2020121-122
impurities
2020121-122
preparations
2020121-122
production process
2020121-122
valsartan
2020121-122
randomised
RCT
20201-8
bias
20201-8
observational
20201-8
research
20201-8
RCT
bias
20201-8
observational
20201-8
randomised
20201-8
research
20201-8
reboundeffect
H2 antagonists
202085-88
PPIs
202085-88
antibiotic-resistant bacteria
202085-88
gastric acid-suppressive agent
202085-88
intestinal colonisation
202085-88
remdesivir
C1-esterase inhibitor
202067-78
anakinra
202067-78
azithromycin
202067-78
chloroquine
202067-78
covid-19
202067-78
hydroxychloroquine
202067-78
icatibant
202067-78
lanadelumab
202067-78
lopinavir
202067-78
ritonavir
202067-78
sars-cov-2
202067-78
tocilizumab
202067-78
valsartan
202067-78
zinc
202067-78
research
RCT
20201-8
bias
20201-8
observational
20201-8
randomised
20201-8
ritonavir
C1-esterase inhibitor
202067-78
anakinra
202067-78
azithromycin
202067-78
chloroquine
202067-78
covid-19
202067-78
hydroxychloroquine
202067-78
icatibant
202067-78
lanadelumab
202067-78
lopinavir
202067-78
remdesivir
202067-78
sars-cov-2
202067-78
tocilizumab
202067-78
valsartan
202067-78
zinc
202067-78
rotator cuff rupture
ACP
202052-55
Achilles tendon rupture
202052-55
PRP
202052-55
autologous conditioned plasma
202052-55
autologous platelet-rich plasma
202052-55
platelet-rich plasma
202052-55
soft tissue injuries
202052-55
tendinopathy
202052-55
sacubitril
Entresto
2020
cardiovascular mortality
2020
enalapril
2020
heart failure
2020
valsartan
2020
sars-cov-2
ACE inhibitors
2020
C1-esterase inhibitor
202067-78
NSAID
2020
anakinra
202067-78
angiotensin II receptor antagonists
2020
azithromycin
202067-78
chloroquine
202067-78
coronavirus
2020
corticosteroids
2020
covid-19
2020
covid-19
202067-78
hydroxychloroquine
202067-78
icatibant
202067-78
lanadelumab
202067-78
lopinavir
202067-78
pioglitazone
2020
remdesivir
202067-78
ritonavir
202067-78
tocilizumab
202067-78
valsartan
202067-78
zinc
202067-78
Shingrix
herpes zoster
202097-101
postherpetic neuralgia
202097-101
vaccination programme
202097-101
vaccine
202097-101
sickle cell disease
acute chest syndrome
202057-64
hydroxycarbamide
202057-64
pain episodes
202057-64
sleep disorders
melatonine
202041-44
soft tissue injuries
ACP
202052-55
Achilles tendon rupture
202052-55
PRP
202052-55
autologous conditioned plasma
202052-55
autologous platelet-rich plasma
202052-55
platelet-rich plasma
202052-55
rotator cuff rupture
202052-55
tendinopathy
202052-55
statistical test
bias
202089-95
consistency check
202089-95
drugs ranking
202089-95
effect modifier
202089-95
network meta-analysis
202089-95
tendinopathy
ACP
202052-55
Achilles tendon rupture
202052-55
PRP
202052-55
autologous conditioned plasma
202052-55
autologous platelet-rich plasma
202052-55
platelet-rich plasma
202052-55
rotator cuff rupture
202052-55
soft tissue injuries
202052-55
tocilizumab
C1-esterase inhibitor
202067-78
anakinra
202067-78
azithromycin
202067-78
chloroquine
202067-78
covid-19
202067-78
hydroxychloroquine
202067-78
icatibant
202067-78
lanadelumab
202067-78
lopinavir
202067-78
remdesivir
202067-78
ritonavir
202067-78
sars-cov-2
202067-78
valsartan
202067-78
zinc
202067-78
type 2 diabetes
omega-3 fatty acids
202079-84
premature birth
202079-84
umbrella review
interventions
2020117-120
overviews
2020117-120
vaccination programme
Shingrix
202097-101
herpes zoster
202097-101
postherpetic neuralgia
202097-101
vaccine
202097-101
vaccine
Shingrix
202097-101
herpes zoster
202097-101
postherpetic neuralgia
202097-101
vaccination programme
202097-101
valsartan
C1-esterase inhibitor
202067-78
Entresto
2020
anakinra
202067-78
azithromycin
202067-78
cardiovascular mortality
2020
chloroquine
202067-78
contaminations
2020121-122
covid-19
202067-78
drug contamination
2020121-122
enalapril
2020
heart failure
2020
hydroxychloroquine
202067-78
icatibant
202067-78
impurities
2020121-122
lanadelumab
202067-78
lopinavir
202067-78
preparations
2020121-122
production process
2020121-122
quality control
2020121-122
remdesivir
202067-78
ritonavir
202067-78
sacubitril
2020
sars-cov-2
202067-78
tocilizumab
202067-78
zinc
202067-78
vitamin B12
mortality rate
202065-66
vitamin B12 deficiency
202065-66
vitamin B12 supplementation
202065-66
vitamin B12 deficiency
mortality rate
202065-66
vitamin B12
202065-66
vitamin B12 supplementation
202065-66
vitamin B12 supplementation
mortality rate
202065-66
vitamin B12
202065-66
vitamin B12 deficiency
202065-66
zinc
C1-esterase inhibitor
202067-78
anakinra
202067-78
azithromycin
202067-78
chloroquine
202067-78
covid-19
202067-78
hydroxychloroquine
202067-78
icatibant
202067-78
lanadelumab
202067-78
lopinavir
202067-78
remdesivir
202067-78
ritonavir
202067-78
sars-cov-2
202067-78
tocilizumab
202067-78
valsartan
202067-78